Casa
asdas

ASAS-HI improvement ≥30%, ASDAS LDA status and ASAS40 response

Por um escritor misterioso

Descrição
ASAS-HI improvement ≥30%, ASDAS LDA status and ASAS40 response
Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial. - Abstract - Europe PMC
ASAS-HI improvement ≥30%, ASDAS LDA status and ASAS40 response
PDF) Treatment response and drug retention rates in 24 195 biologic-naïve patients with axial spondyloarthritis initiating TNFi treatment: routine care data from 12 registries in the EuroSpA collaboration
ASAS-HI improvement ≥30%, ASDAS LDA status and ASAS40 response
UCB Presents New Five-Year Data on BIMZELX® (bimekizumab-bkzx) in Ankylosing Spondylitis at ACR Convergence 2023
ASAS-HI improvement ≥30%, ASDAS LDA status and ASAS40 response
Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial. - Abstract - Europe PMC
ASAS-HI improvement ≥30%, ASDAS LDA status and ASAS40 response
Effect of body mass index on treatment response of biologic/targeted-synthetic DMARDs in patients with rheumatoid arthritis, psoriatic arthritis or axial spondyloarthritis. A systematic review - ScienceDirect
ASAS-HI improvement ≥30%, ASDAS LDA status and ASAS40 response
The Brazilian Society of Rheumatology guidelines for axial spondyloarthritis – 2019, Advances in Rheumatology
ASAS-HI improvement ≥30%, ASDAS LDA status and ASAS40 response
Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial
ASAS-HI improvement ≥30%, ASDAS LDA status and ASAS40 response
Long-term safety and clinical outcomes of certolizumab pegol treatment in patients with active non-radiographic axial spondyloarthritis: 3-year results from the phase 3 C-axSpAnd study
ASAS-HI improvement ≥30%, ASDAS LDA status and ASAS40 response
Assessment of SpondyloArthritis international Society criteria for 20%
ASAS-HI improvement ≥30%, ASDAS LDA status and ASAS40 response
Disease Control Data, Ankylosing Spondylitis
ASAS-HI improvement ≥30%, ASDAS LDA status and ASAS40 response
Disease Control Data, Ankylosing Spondylitis
ASAS-HI improvement ≥30%, ASDAS LDA status and ASAS40 response
AS Criteria: Diagnosis (ASAS), Disease Activity (ASDAS), Radiographic Progression (mSASSS) - Arthritis Rheumatism
ASAS-HI improvement ≥30%, ASDAS LDA status and ASAS40 response
Disease Control Data, Ankylosing Spondylitis
de por adulto (o preço varia de acordo com o tamanho do grupo)